Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
125.17
+2.59 (2.11%)
At close: Jul 1, 2026, 4:00 PM EDT
127.00
+1.83 (1.46%)
After-hours: Jul 1, 2026, 6:28 PM EDT
Protagonist Therapeutics Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Protagonist Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $118.69. The average 1-year stock price forecast is 5.18% lower than the current stock price, while the lowest is $100 (-20.11%) and the highest is $137 (+9.45%).
Price Target: $118.69 (-5.18%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Protagonist Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 8 | 9 | 9 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 22, 2026 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $97 → $110 | Hold | Maintains | $97 → $110 | -12.12% | Jun 11, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $106 → $113 | Buy | Maintains | $106 → $113 | -9.72% | May 14, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $117 | Buy | Reiterates | $117 | -6.53% | May 11, 2026 |
| Citi | Citi | Buy Maintains $125 → $130 | Buy | Maintains | $125 → $130 | +3.86% | May 10, 2026 |
Financial Forecast
Revenue This Year
509.21M
from 46.02M
Increased by 1,006.59%
Revenue Next Year
159.78M
from 509.21M
Decreased by -68.62%
EPS This Year
4.17
from -2.05
EPS Next Year
-0.68
from 4.17
EPS and Forward PE are based on non-GAAP adjusted numbers.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 586.6M | ||
| Avg | 509.2M | ||
| Low | 129.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1,174.8% | ||
| Avg | 1,006.6% | ||
| Low | 180.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 5.88 | ||
| Avg | 4.17 | ||
| Low | -1.00 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |